Table 3.
AMHR2 | AR | ESR1 | FOS | KISS1 | OPRK1 | PDYN | PGR | VGLUT2 | VGAT | TAC2 | TAC3R | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
KISS1 cells | PNV male | 8.0 ± 1.2 | 9.8 ± 0.8 b | 13.6 ± 0.6 b | 6.4 ± 0.7 | 9.4 ± 0.5 | 8.2 ± 0.2 | 23.3 ± 0.6 | 15.0 ± 0.5 | 19.5 ± 0.9 | 12.8 ± 0.1 | 15.2 ± 0.6 | 10.4 ± 0.6 |
PNV female | 4.0 ± 0.8 | 6.0 ± 0.1 | 17.0 ± 0.8 | 7.1 ± 0.3 | 11.9 ± 0.9 | 7.1 ± 0.3 | 20.1 ± 1.2 | 18.0 ± 1.2 | 17.0 ± 1.3 | 12.6 ± 0.8 | 18.2 ± 0.8 | 11.3 ± 0.9 | |
PNA female | 4.4 ± 0.4 | 8.4 ± 0.3 b | 16.5 ± 0.6a | 6.1 ± 1.0 | 11.7 ± 0.6 | 11.6 ± 1.0 a,b | 15.4 ± 0.6 a,b | 12.9 ± 0.8 a,b | 14.2 ± 0.4 | 12.9 ± 0.6 | 18.3 ± 0.6 | 13.0 ± 0.8 | |
VGLUT2 cells | PNV Male | 4.2 ± 0.3 | 7.3 ± 0.7 | 8.1 ± 0.5 | 10.3 ± 1.0 | N/A | 6.5 ± 0.2 | 12.9 ± 1.4 | 10.3 ± 0.6 | 13.0 ± 0.9 | 14.8 ± 0.6 | 7.2 ± 1.0 | 7.4 ± 0.9 |
PNV Female | 3.3 ± 0.1 | 6.9 ± 0.3 | 10.1 ± 0.7 | 9.4 ± 1.2 | N/A | 7.1 ± 0.5 | 11.6 ± 0.7 | 11.2 ± 0.7 | 11.5 ± 0.6 | 14.5 ± 0.3 | 7.3 ± 0.7 | 6.9 ± 0.8 | |
PNA Female | 3.3 ± 0.2 | 7.7 ± 0.4 | 9.9 ± 0.3 | 7.8 ± 0.4 | N/A | 7.1 ± 0.3 | 11.0 ± 0.5 | 8.7 ± 0.4 b | 12.1 ± 0.7 | 15.5 ± 0.2 | 8.7 ± 1.0 | 7.2 ± 1.0 | |
VGAT cells | PNV Male | 4.2 ± 0.9 | 6.1 ± 0.3 | 7.5 ± 0.6 | 10.0 ± 0.6 | N/A | 6.3 ± 0.2 | 9.9 ± 0.8 | 8.9 ± 0.4 | 10.6 ± 0.2 | 14.8 ± 0.6 | 6.9 ± 0.7 | 6.1 ± 0.8 |
PNV Female | 3.3 ± 0.1 | 5.6 ± 0.2 | 8.9 ± 0.6 | 9.2 ± 0.6 | N/A | 6.6 ± 0.3 | 8.3 ± 0.2 | 9.8 ± 0.3 | 9.3 ± 0.7 | 14.5 ± 0.3 | 6.9 ± 0.5 | 5.5 ± 0.2 | |
PNA Female | 3.4 ± 0.2 | 6.4 ± 0.2 | 8.9 ± 0.3 | 7.1 ± 0.4 a | N/A | 6.7 ± 0.3 | 8.1 ± 0.1 a | 8.0 ± 0.5 b | 9.8 ± 0.8 | 15.5 ± 0.2 | 7.2 ± 0.5 | 6.1 ± 0.7 |
Abbreviations: ARC, arcuate nucleus; N/A, not assessable; PNA, prenatal androgen-treated; PNV, prenatal vehicle; SEM, standard error of the mean.
a significantly different vs PNV male,
b significantly different vs PNV female. N/A = not assessable.